Arrowstreet Capital
NRIX icon

Arrowstreet Capital’s Nurix Therapeutics NRIX Stock Holding History

Arrowstreet Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
+477,141
New +$8.13M 0.01% 1030
2024
Q3 		– Sell
-60,084
Closed -$1.25M – 1826
2024
Q2 		$1.25M Sell
60,084
-127,659
-68% -$1.99M ﹤0.01% 1174
2024
Q1 		$2.76M Sell
187,743
-7,393
-4% -$79.5K ﹤0.01% 1057
2023
Q4 		$2.01M Buy
+195,136
New +$1.34M ﹤0.01% 966

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arrowstreet Capital's NRIX Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 477,141 shares worth $11.6M. The stake represents 0.01% of the portfolio and ranks #1030 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in NRIX as recently as Q2 2024.

Arrowstreet Capital first reported a position in NRIX in Q4 2023 and has held it in 4 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Arrowstreet Capital held 477,141 shares of Nurix Therapeutics worth $11.6M as of Q2 2026.
  • Nurix Therapeutics was a new Arrowstreet Capital position in Q2 2026.
  • Nurix Therapeutics made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1030 holding.
  • Arrowstreet Capital first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.